Skip to main content
Top
Published in: BMC Nephrology 1/2013

Open Access 01-12-2013 | Research article

Differential effects of phosphate binders on pre-dialysis serum bicarbonate in end-stage kidney disease patients on maintenance haemodialysis

Authors: Zaw Thet, Aung Ko WIN, Eugenie Pedagogos, Jennifer Beavis, Sandra Crikis, Craig Nelson

Published in: BMC Nephrology | Issue 1/2013

Login to get access

Abstract

Background

Phosphate binders’ constituents have alkalotic or acidotic properties and may contribute to acid base balance in haemodialysis patients. This study aimed to investigate the differential effects of phosphate binders on pre-dialysis serum bicarbonate in End Stage Kidney Disease patients on maintenance haemodialysis.

Methods

Stable out-patients having satellite haemodialysis for at least 3 months were retrospectively studied for 18 months, excluding those with other medical causes for metabolic acidosis. Blood results were censored for inpatient episodes, at the time of death, renal transplant or dialysis modality change. Multivariable multilevel mixed-effects linear regression was used and five groups of phosphate binders were compared: Group A(Calcium (Ca) and/or Aluminium (Al) binders); B(Sevelamer hydrochloride (SH) alone); C(lanthanum carbonate (LC) alone); D(SH and Ca/Al), E(LC and Ca/Al).

Results

Of 320 patients, 292 were eligible for analysis with a mean follow-up of 15.54 (standard deviation, SD 3.98) months. Similar mean pre-dialysis serum levels of bicarbonate were observed at all 6 month-interval analyses. At 18th months, observed mean serum bicarbonate levels in mmol/L were Group B: 21.58 (SD 2.82, P<0.001), C: 23.29 (SD 2.80, P=0.02), D: 21.56 (SD 3.00, P<0.001), and E: 21.29 (SD 3.62, P=0.92) compared with Group A: 22.98 (SD 2.77). Mean serum bicarbonate was related to total SH dose in mmol/L: 22.34 (SD 2.56) for SH <2.5 g/day, 21.61 (SD 2.62) for SH 2.5-4.8 g/day, 21.04 (SD 3.31) for SH >4.8 g/day compared with 22.85 (SD 2.91) for non-users; P-trend<0.001.

Conclusions

Phosphate binders’ constituents may contribute to/protect against a predisposition to pre-dialysis metabolic acidosis. This may be dose dependant in patients taking Sevelamer Hydrochloride.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kraut JA, Kurtz I: Metabolic acidosis of CKD: diagnosis, clinical characteristics, and treatment. Am J Kidney Dis. 2005, 45 (6): 978-993. 10.1053/j.ajkd.2005.03.003.CrossRefPubMed Kraut JA, Kurtz I: Metabolic acidosis of CKD: diagnosis, clinical characteristics, and treatment. Am J Kidney Dis. 2005, 45 (6): 978-993. 10.1053/j.ajkd.2005.03.003.CrossRefPubMed
2.
go back to reference Mehrotra RD KOPPLEJ, Wolfson M: Metabolic acidosis in maintenance dialysis patients: clinical considerations. Kidney Int. 2003, 64 (S88): S13-S26. 10.1046/j.1523-1755.2003.08802.x.CrossRef Mehrotra RD KOPPLEJ, Wolfson M: Metabolic acidosis in maintenance dialysis patients: clinical considerations. Kidney Int. 2003, 64 (S88): S13-S26. 10.1046/j.1523-1755.2003.08802.x.CrossRef
4.
go back to reference Bommer J, Locatelli F, Satayathum S, Keen ML, Goodkin DA, Saito A, Akiba T, Port FK, Young EW: Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004, 44 (4): 661-671.CrossRefPubMed Bommer J, Locatelli F, Satayathum S, Keen ML, Goodkin DA, Saito A, Akiba T, Port FK, Young EW: Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004, 44 (4): 661-671.CrossRefPubMed
5.
go back to reference Wu D, Kilpatrick R, Dadres S, McAllister CJ, Kopple JD, Kalantarâ€Zadeh K: Association between serum bicarbonate and death in hemodialysis patients: Is it better to be acidotic or alkalotic?. Hemodial Int. 2005, 9 (1): 87-87.CrossRef Wu D, Kilpatrick R, Dadres S, McAllister CJ, Kopple JD, Kalantarâ€Zadeh K: Association between serum bicarbonate and death in hemodialysis patients: Is it better to be acidotic or alkalotic?. Hemodial Int. 2005, 9 (1): 87-87.CrossRef
6.
go back to reference The Renal Association: Laboratory and clinical indices of dialysis adequacy other than dialysis dose. 2009, Guidlines 6.3 - HD: Pre-Dialysis serum bicarbonate concentrations (Updated 2009 December). Available from http://www.renal.org/home.aspx The Renal Association: Laboratory and clinical indices of dialysis adequacy other than dialysis dose. 2009, Guidlines 6.3 - HD: Pre-Dialysis serum bicarbonate concentrations (Updated 2009 December). Available from http://​www.​renal.​org/​home.​aspx
7.
go back to reference Sprague SM: A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate*. Curr Med Res Opin®. 2007, 23 (12): 3167-3175. 10.1185/030079907X242719.CrossRef Sprague SM: A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate*. Curr Med Res Opin®. 2007, 23 (12): 3167-3175. 10.1185/030079907X242719.CrossRef
8.
go back to reference Raggi P, Vukicevic S, Moysés RM, Wesseling K, Spiegel DM: Ten-year experience with sevelamer and calcium salts as phosphate binders. Clin J Am Soc Nephrol. 2010, 5: 31-40. 10.2215/CJN.05880809.CrossRef Raggi P, Vukicevic S, Moysés RM, Wesseling K, Spiegel DM: Ten-year experience with sevelamer and calcium salts as phosphate binders. Clin J Am Soc Nephrol. 2010, 5: 31-40. 10.2215/CJN.05880809.CrossRef
9.
go back to reference Brezina B, Qunibi WY, Nolan CR: Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications. Kidney Int. 2004, 66: S39-S45. 10.1111/j.1523-1755.2004.09007.x.CrossRef Brezina B, Qunibi WY, Nolan CR: Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications. Kidney Int. 2004, 66: S39-S45. 10.1111/j.1523-1755.2004.09007.x.CrossRef
10.
go back to reference De Santo NG, Frangiosa A, Anastasio P, Marino A, Correale G, Perna A, Di Stazio E, Stellato D, Santoro D, Di Meglio E: Sevelamer worsens metabolic acidosis in hemodialysis patients. Journal of nephrology. 2006, 19: S108-PubMed De Santo NG, Frangiosa A, Anastasio P, Marino A, Correale G, Perna A, Di Stazio E, Stellato D, Santoro D, Di Meglio E: Sevelamer worsens metabolic acidosis in hemodialysis patients. Journal of nephrology. 2006, 19: S108-PubMed
11.
go back to reference Sonikian MA, Pani IT, Iliopoulos AN, Koutala KG, Marioli SI, Vlassopoulos DA: Metabolic acidosis aggravation and hyperkaliemia in hemodialysis patients treated by sevelamer hydrochloride. Renal failure. 2005, 27 (2): 143-147.CrossRefPubMed Sonikian MA, Pani IT, Iliopoulos AN, Koutala KG, Marioli SI, Vlassopoulos DA: Metabolic acidosis aggravation and hyperkaliemia in hemodialysis patients treated by sevelamer hydrochloride. Renal failure. 2005, 27 (2): 143-147.CrossRefPubMed
12.
go back to reference Oka Y, Miyazaki M, Takatsu S, Kunitomo K-i, Uno F, Maruyama M, Matsuda H: Sevelamer Hydrochloride Exacerbates Metabolic Acidosis in Hemodialysis Patients, Depending on the Dosage. Ther Apher Dial. 2007, 11 (2): 107-113. 10.1111/j.1744-9987.2007.00432.x.CrossRefPubMed Oka Y, Miyazaki M, Takatsu S, Kunitomo K-i, Uno F, Maruyama M, Matsuda H: Sevelamer Hydrochloride Exacerbates Metabolic Acidosis in Hemodialysis Patients, Depending on the Dosage. Ther Apher Dial. 2007, 11 (2): 107-113. 10.1111/j.1744-9987.2007.00432.x.CrossRefPubMed
13.
go back to reference Sonikian M, Metaxaki P, Iliopoulos A, Marioli S, Vlassopoulos D: Long-term management of sevelamer hydrochloride-induced metabolic acidosis aggravation and hyperkalemia in hemodialysis patients. Renal failure. 2006, 28 (5): 411-418. 10.1080/08860220600599092.CrossRefPubMed Sonikian M, Metaxaki P, Iliopoulos A, Marioli S, Vlassopoulos D: Long-term management of sevelamer hydrochloride-induced metabolic acidosis aggravation and hyperkalemia in hemodialysis patients. Renal failure. 2006, 28 (5): 411-418. 10.1080/08860220600599092.CrossRefPubMed
14.
go back to reference Savica V, Santoro D, Monardo P, Mallamace A, Bellinghieri G: Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis. Ther Clin Risk Manag. 2008, 4 (4): 821-PubMedPubMedCentral Savica V, Santoro D, Monardo P, Mallamace A, Bellinghieri G: Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis. Ther Clin Risk Manag. 2008, 4 (4): 821-PubMedPubMedCentral
15.
go back to reference Hutchison AJ, Barnett ME, Krause R, Kwan JTC, Siami GA: Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Nephron Clin Pract. 2008, 110 (1): c15-c23. 10.1159/000149239.CrossRefPubMedPubMedCentral Hutchison AJ, Barnett ME, Krause R, Kwan JTC, Siami GA: Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Nephron Clin Pract. 2008, 110 (1): c15-c23. 10.1159/000149239.CrossRefPubMedPubMedCentral
16.
go back to reference StataCorp: Stata Statistical Software: Release 11. College Station, TX: StataCorp LP. 2009 StataCorp: Stata Statistical Software: Release 11. College Station, TX: StataCorp LP. 2009
17.
go back to reference National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003, 42 (3): 1-201. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003, 42 (3): 1-201.
18.
go back to reference RAULT R: Optimal dialysate bicarbonate during hemodialysis. ASAIO J. 1991, 37 (3): M372- RAULT R: Optimal dialysate bicarbonate during hemodialysis. ASAIO J. 1991, 37 (3): M372-
19.
go back to reference Zucchelli P, Santoro A: Correction of acid–base balance by dialysis. Kidney Int Suppl. 1993, 41: S179-PubMed Zucchelli P, Santoro A: Correction of acid–base balance by dialysis. Kidney Int Suppl. 1993, 41: S179-PubMed
20.
go back to reference Williams A, Dittmer I, McArley A, Clarke J: High bicarbonate dialysate in haemodialysis patients: effects on acidosis and nutritional status. Nephrol Dial Transplant. 1997, 12 (12): 2633-10.1093/ndt/12.12.2633.CrossRefPubMed Williams A, Dittmer I, McArley A, Clarke J: High bicarbonate dialysate in haemodialysis patients: effects on acidosis and nutritional status. Nephrol Dial Transplant. 1997, 12 (12): 2633-10.1093/ndt/12.12.2633.CrossRefPubMed
21.
go back to reference Agroyannis B, Fourtounas C, Tzanatos H, Dalamangas A, Vlahakos D: Relationship Between Interdialytic Weight Gain and Acid†Base Status in Hemodialysis by Bicarbonate. Artificial organs. 2002, 26 (4): 385-387. 10.1046/j.1525-1594.2002.06883.x.CrossRefPubMed Agroyannis B, Fourtounas C, Tzanatos H, Dalamangas A, Vlahakos D: Relationship Between Interdialytic Weight Gain and Acid†Base Status in Hemodialysis by Bicarbonate. Artificial organs. 2002, 26 (4): 385-387. 10.1046/j.1525-1594.2002.06883.x.CrossRefPubMed
22.
go back to reference Oettinger CW, Oliver JC: Normalization of uremic acidosis in hemodialysis patients with a high bicarbonate dialysate. J Am Soc Nephrol. 1993, 3 (11): 1804-1807.PubMed Oettinger CW, Oliver JC: Normalization of uremic acidosis in hemodialysis patients with a high bicarbonate dialysate. J Am Soc Nephrol. 1993, 3 (11): 1804-1807.PubMed
23.
go back to reference Roderick PJ, Willis NS, Blakeley S, Jones C, Tomson C: Correction of chronic metabolic acidosis for chronic kidney disease patients. Cochrane Database of Systematic Reviews. 2007, Issue 1. Art. No.: CD001890. DOI: 10.1002/14651858.CD001890.pub3 Roderick PJ, Willis NS, Blakeley S, Jones C, Tomson C: Correction of chronic metabolic acidosis for chronic kidney disease patients. Cochrane Database of Systematic Reviews. 2007, Issue 1. Art. No.: CD001890. DOI: 10.1002/14651858.CD001890.pub3
24.
go back to reference Noh U, Yi JH, Han SW, Kim HJ: Varying Dialysate Bicarbonate Concentrations in Maintenance Hemodialysis Patients Affect Post-dialysis Alkalosis but not Pre-dialysis Acidosis. Electrolyte & Blood Pressure. 2007, 5 (2): 95-101. 10.5049/EBP.2007.5.2.95.CrossRef Noh U, Yi JH, Han SW, Kim HJ: Varying Dialysate Bicarbonate Concentrations in Maintenance Hemodialysis Patients Affect Post-dialysis Alkalosis but not Pre-dialysis Acidosis. Electrolyte & Blood Pressure. 2007, 5 (2): 95-101. 10.5049/EBP.2007.5.2.95.CrossRef
25.
go back to reference Fan S, Ross C, Mitra S, Kalra P, Heaton J, Hunter J, Plone M, Pritchard N: A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis. Nephrol Dial Transplant. 2009, 24 (12): 3794-10.1093/ndt/gfp372.CrossRefPubMedPubMedCentral Fan S, Ross C, Mitra S, Kalra P, Heaton J, Hunter J, Plone M, Pritchard N: A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis. Nephrol Dial Transplant. 2009, 24 (12): 3794-10.1093/ndt/gfp372.CrossRefPubMedPubMedCentral
26.
go back to reference Hutchison AJ, Laville M: Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden. Nephrol Dial Transplant. 2008, 23 (11): 3677-10.1093/ndt/gfn310.CrossRefPubMedPubMedCentral Hutchison AJ, Laville M: Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden. Nephrol Dial Transplant. 2008, 23 (11): 3677-10.1093/ndt/gfn310.CrossRefPubMedPubMedCentral
27.
go back to reference Sprague S, Ross E, Nath S, Zhang P, Pratt R, Krause R: Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. Clin Nephrol. 2009, 72 (4): 252-258.CrossRefPubMed Sprague S, Ross E, Nath S, Zhang P, Pratt R, Krause R: Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. Clin Nephrol. 2009, 72 (4): 252-258.CrossRefPubMed
28.
go back to reference Filiopoulos V, Koutis I, Trompouki S, Hadjiyannakos D, Lazarou D, Vlassopoulos D: Lanthanum Carbonate Versus Sevelamer Hydrochloride: Improvement of Metabolic Acidosis and Hyperkalemia in Hemodialysis Patients. Ther Apher Dial. 2011, 15 (1): 20-27. 10.1111/j.1744-9987.2010.00868.x.CrossRefPubMed Filiopoulos V, Koutis I, Trompouki S, Hadjiyannakos D, Lazarou D, Vlassopoulos D: Lanthanum Carbonate Versus Sevelamer Hydrochloride: Improvement of Metabolic Acidosis and Hyperkalemia in Hemodialysis Patients. Ther Apher Dial. 2011, 15 (1): 20-27. 10.1111/j.1744-9987.2010.00868.x.CrossRefPubMed
Metadata
Title
Differential effects of phosphate binders on pre-dialysis serum bicarbonate in end-stage kidney disease patients on maintenance haemodialysis
Authors
Zaw Thet
Aung Ko WIN
Eugenie Pedagogos
Jennifer Beavis
Sandra Crikis
Craig Nelson
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2013
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-14-205

Other articles of this Issue 1/2013

BMC Nephrology 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.